Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Single Dose and Steady-State Pharmacokinetic Profiles of Nifedipine Coat-Core Tablets in Healthy Elderly and Young Volunteers

  • 10 Accesses

  • 2 Citations

Summary

21 healthy young and 21 healthy elderly volunteers took part in this nonrandomised, open study to determine and compare the single dose and steady-state pharmacokinetic profiles of nifedipine coat-core (CC) tablets in young and elderly subjects. All volunteers received one nifedipine CC tablet (60mg) once daily for 7 days at 0700h. The single dose and steady-state pharmacokinetic profiles were studied on days 1 and 7, respectively, when serial blood samples were drawn over a 24-hour period for determination of plasma nifedipine concentrations.

After a single dose the extent of absorption of nifedipine appears similar in the young and the elderly, but the rate of absorption appears lower in the elderly compared with the young. The steady-state profiles show a somewhat higher accumulation of the drug in the elderly compared with the young, as well as a lower rate of absorption in the elderly. However, the accumulation of the drug in both the elderly and the young is small in clinical terms, so that a dose reduction for otherwise healthy elderly subjects does not seem to be required.

This is a preview of subscription content, log in to check access.

References

  1. Crome P, Müller FO, Wijayawardhana P, Groenewoud G, Hundt HKL, et al. The single dose and steady state pharmacokinetic profiles of the nifedipine GITS tablet in healthy elderly and young volunteers. Drug Investigation 5(3): 193–199, 1993

  2. Kleinbloesem CH, van Brummelen P, van der Linde JA, Voogd PJ, Breimer DD. Nifedipine: kinetics and dynamics in healthy subjects. Clinical Pharmacology and Therapeutics 35: 742–749, 1984

  3. Murdoch D, Brogden RN. Sustained release nifedipine formulations. Drugs 41: 737–779, 1991

  4. Raemsch KD, Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension 5 (Suppl. II): 18–24, 1983

  5. Robertson DRC, Waller DG, Renwick AG, George CF. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. British Journal of Clinical Pharmacology 25: 297–305, 1988

  6. Scott M, Castleden CM, Adam HK, Smith RP, Fitzsimons TJ. The effect of ageing on the disposition of nifedipine and atenolol. British Journal of Clinical Pharmacology 25: 289–296, 1988

  7. Steinijans VW. Pharmacokinetic characterization of controlled-release formulations. European Journal of Drug Metabolism and Pharmacokinetics 15: 173–181, 1990

  8. Steinijans VW, Trautmann H, Johnson E, Beier W. Theophylline steady-state pharmacokinetics: recent concepts and their application in chronotherapy of reactive airway diseases. Chronobiology International 4: 331–347, 1987

Download references

Author information

Correspondence to Prof. F. O. Müller.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Müller, F.O., Henry, J., Schall, R. et al. Single Dose and Steady-State Pharmacokinetic Profiles of Nifedipine Coat-Core Tablets in Healthy Elderly and Young Volunteers. Drug Invest. 5, 243–249 (1993). https://doi.org/10.1007/BF03259588

Download citation

Keywords

  • Nifedipine
  • Drug Invest
  • Elderly Volunteer
  • Young Volunteer
  • Accumulation Ratio